New Strategies for Improving the Cognitive Functions in Different Types of Dementia
A special issue of Future Pharmacology (ISSN 2673-9879).
Deadline for manuscript submissions: closed (15 June 2023) | Viewed by 292
Special Issue Editors
Interests: pharmacology; CV system; neurodegenerative disorders; diabetes mellitus; retinopathy; herbals; antioxidants; oxidative stress
Special Issues, Collections and Topics in MDPI journals
Interests: pharmacology; herbals; plant extracts; polyphenols; SIRT1; antioxidants; oxidative stress; apoptosis
Special Issue Information
Dear Colleagues,
Dementia and its most common cause, Alzheimer's disease, place a significant burden on health care. Impairment of cognitive function appears in the early stages, but its recognition and treatment are still not completely resolved.
The incidence and prevalence of the disease is increasing and is projected to affect nearly 100 million people by 2050. Several studies are underway on the subject; however, the new formulations have not been shown to be effective in severe or advanced stages of the disease, and some of the studied drugs have serious side effects. As a result, only one of the drugs has been approved by the FDA. This molecule is able to delay the clinical decline. However, molecules that would affect or improve cognitive function have not yet been marketed.
The aim of our special issue is to publish research results that report new hypotheses related to the pathogenesis of the disease, new pharmacological target molecules, new therapeutic strategies, and possibly alternative treatment options. Furthermore, studies and results about the cognitive function improvement are also hoped for.
Dr. Rita Kiss
Prof. Dr. Annamaria Pallag
Dr. Daniel Priksz
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Future Pharmacology is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cognitive function
- alzheimer disease
- dementia
- natural products
- gene therapy
- biological therapy
- new target molecules
